STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...

Annual Report/Annual ResultsFormycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position 27.03.2025 / 06:30 CET/CESTThe ...

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...

Steqeyma, a biosimilar of Johnson & Johnson's blockbuster drug Stelara, received full-label approval from the US Food and Drug Administration last December for plaque psoriasis, psoriatic ...

Navitus will remove Stelara from formulary on July 1, 2025. Stelara, the brand name of the drug ustekinumab, is a popular treatment for plaque psoriasis, psoriatic arthritis, ulcerative colitis ...

JERSEY CITY, NJ, USA I March 12, 2025 I Celltrion today announced the U.S. launch of STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab), following approval by the U.S. Food and ...

It encompasses all indications approved for the STELARA® reference product ... 45mg/0.5 mL or 90mg/1 mL solution in a single-dose, prefilled syringe. The intravenous infusion is provided as a ...

It encompasses all indications approved for the STELARA ® reference product ... 45mg/0.5 mL or 90mg/1 mL solution in a single-dose, prefilled syringe. The intravenous infusion is provided ...

STEQEYMA ®, one of the first-wave biosimilars to STELARA ®, is now available in the U.S. Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale ...

A new report from the NC Department of Health and Human Services on the programs around the state reveals that most counties have such programs – ones that give out clean syringes and other drug ...

Stelara (ustekinumab, Janssen) is an interleukin (IL)-12 and IL-23 inhibitor approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

at an 85% discount off Stelara, and eligible patients may receive their medication at no cost or may be eligible for assistance through Teva’s programs. Selarsdi, approved by the FDA in October 2024, ...